Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Avxl save search
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
Published: 2023-12-19 (Crawled : 12:30) - globenewswire.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 2.39%
H: 16.11%
C: 10.56%
disease blarcamesine alzheimer’s application anavex agreement submission
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
Published: 2023-11-20 (Crawled : 13:00) - globenewswire.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 11.64%
H: 1.07%
C: 0.0%
disease blarcamesine alzheimer’s anavex submission anavex®2-73
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 0.78%
H: 10.25%
C: 8.12%
anavex disease life alzheimer’s publication sciences potential
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology
Published: 2023-09-14 (Crawled : 12:30) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 4.18%
H: 5.14%
C: -0.38%
anavex disease blarcamesine alzheimer’s trial biomarkers anavex®2-73
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Published: 2023-09-14 (Crawled : 12:00) - globenewswire.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 4.18%
H: 5.14%
C: -0.38%
anavex disease blarcamesine alzheimer’s trial anavex®2-73
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Published: 2023-07-24 (Crawled : 05:00) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: -2.1%
H: 3.79%
C: 3.29%
disease companies neurodegenerative
Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -1.36%
anavex disease anavex®2-73 study rett syndrome
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published: 2023-04-19 (Crawled : 15:00) - prnewswire.com
NVO | News | $124.095 -0.35% 660K
|
Health Technology
|
| O: -3.51%
H: 1.28%
C: 0.74%
LLY | News | $749.39 -0.18% 350K
|
Health Technology
|
| O: 0.17%
H: 0.2%
C: -0.02%
VTGN | $4.67 55K
|
Health Technology
|
| O: 0.0%
H: 2.59%
C: -0.49%
DNLI | $16.68 -0.83% 89K
|
Health Technology
|
| O: -1.11%
H: 1.31%
C: 0.56%
BIVI | $0.4739 0.53% 840K
|
Health Technology
|
| O: -0.24%
H: 4.29%
C: 0.49%
BIIB | $191.63 -0.28% 170K
|
Health Technology
|
| O: -0.39%
H: 0.4%
C: -0.14%
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.05%
H: 13.81%
C: 11.81%
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: -0.74%
H: 2.73%
C: 1.61%
disease companies parkinson's pipeline space trial
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
Published: 2022-12-02 (Crawled : 02:00) - globenewswire.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 41.71%
H: 5.25%
C: -4.14%
anavex global disease alzheimer’s study phase 2b anavex®2-73
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
Published: 2022-10-17 (Crawled : 12:20) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 4.43%
H: 14.0%
C: 12.83%
anavex anavex®2-73 trials sciences disease life alzheimer’s presentation phase 2b
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
Published: 2022-08-23 (Crawled : 13:00) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 0.91%
H: 2.9%
C: 1.6%
sciences disease alzheimer's life anavex publication
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 0.4%
H: 6.32%
C: 5.24%
pdd-001 anavex phase 2 dementia anavex®2-73 parkinson conference presentation disease life science international tiona biomarkers
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease
Published: 2021-11-10 (Crawled : 12:15) - globenewswire.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: -7.28%
H: 3.35%
C: -1.43%
disease alzheimer life science anavex alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s DiseaseThe Company anticipates topline data in the second half of 2022
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 0.17%
H: 3.65%
C: 2.32%
disease alzheimer phase 2 topline life science phase 2b trial anavex®2-73 anavex alzheimer’s alzheimer's
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease
Published: 2021-07-29 (Crawled : 11:00) - anavex.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 2.67%
H: 0.27%
C: -16.6%
disease alzheimer life science anavex®2-73 anavex alzheimer’s alzheimer's disease alzheimer's biomarkers
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published: 2021-06-28 (Crawled : 12:00) - anavex.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 20.0%
H: 6.06%
C: -2.83%
disease treatment phase 2 dementia correlation parkinson life science trial anavex®2-73 anavex biomarkers
Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2030, Foresees DelveInsight
Published: 2021-06-16 (Crawled : 18:00) - prnewswire.com
DNLI | $16.68 -0.83% 89K
|
Health Technology
|
| O: 0.16%
H: 1.21%
C: -0.12%
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 4.61%
H: 18.52%
C: 16.1%
disease alzheimer growth set alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease
Published: 2021-06-14 (Crawled : 12:00) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 7.74%
H: 33.14%
C: 25.69%
disease alzheimer treatment dating life science anavex®2-73 anavex alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 4.51%
H: 0.41%
C: -0.46%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex enroll alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
Published: 2021-03-31 (Crawled : 12:00) - anavex.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 1.92%
H: 7.76%
C: 4.55%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
SINT | $0.0504 35.12% 300M
|
Health Technology
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.